Sarepta | search
Click here to view Sarepta news from 60+ newspapers.
Bookmark or Share- Sarepta Therapeutics Announces First Quarter 2024 Financial Results and ...Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is ...
- Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy ...CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Feb. 16, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS (delandistrogene mo...
- Sarepta Therapeutics | Biopharmaceutical Company for Rare DiseasesSarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine. Our platforms include: gene therapy, RNA technologies, and gene editing. We are in a daily race to save lives stolen or impacted by rare disease.
- Sarepta Therapeutics, Inc. (SRPT) - Yahoo FinanceFind the latest Sarepta Therapeutics, Inc. (SRPT) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene ...CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jun. 22, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of...
More
